Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab Extension Study for RRMS
NCT00930553Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2009
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Sanofi. Started Aug 2009; status: completed.
02
Drugs
alemtuzumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00930553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00930553.